EDX Medical Group Plc Placing to raise £1,725,000

 
TIDMEDX 
 
This announcement contains inside information as stipulated under 
the UK version of the Market Abuse Regulation No 596/2014 which is part of 
English law by virtue of the European (Withdrawal) Act 2018, as amended.  On 
publication of this announcement via a regulatory information service, this 
information is considered to be in the public domain and such persons shall 
therefore cease to be in possession of inside information. 
 
                            LONDON: April 26, 2023 
 
                             EDX Medical Group Plc 
 
                          Placing to raise £1,725,000 
 
EDX Medical Group plc ("EDX Medical" or the "Company"), which develops 
innovative digital diagnostic products and services supporting personalised 
treatment solutions for cancer, heart disease, neurology and infectious 
diseases, is pleased to announce that the Company has raised a total of £ 
1,725,000 via the issue of 28,750,000 new ordinary shares in the Company, at 6 
pence per share ("Placing"). 
 
Bridgemere Securities Ltd ("Bridgemere") has invested £1,500,000 in the 
Placing. Further, Bridgemere has also bought a further 7,720,000 ordinary 
shares in the market between 20 and 21 April 2023. Bridgemere is now the second 
largest shareholder in EDX Medical following its investment. 
 
Paul Thandi, CBE, DL, has invested £200,000 in the Placing. 
 
Robert Marshall, founder and executive chairman of Martlet Capital, also 
increased his shareholding in the Company investing a further £25,000 in the 
Placing. 
 
Professor Sir Christopher Evans, founder of EDX Medical, said: "We are 
delighted that experienced investors such as Bridgemere - led by the renowned 
Steve Morgan - as well as Paul Thandi and Robert Marshall share our vision for 
the company and are investing in the innovations we are delivering in digital 
diagnostics, which we believe will make a significant contribution to the 
development of advanced digital diagnostic solutions to accelerate the 
availability of cost-effective personalised treatments for patients with a 
range of major diseases." 
 
Paul Thandi has been CEO of the NEC Group for 16 years, spearheading its 
acquisition by Blackstone in 2021 for £800m. He is an experienced board 
director, investor and philanthropist who supports a number of charitable 
causes including cancer charities. 
 
Application has been made for the 28,750,000 Placing shares to be admitted to 
trading on or about  3 May 2023. 
 
Total Voting Rights 
 
In accordance with the Financial Conduct Authority's Disclosure and 
Transparency Rules, the Company hereby announces that following the placing, it 
has 281,250,000 ordinary shares of 1 pence each ("Ordinary Shares") in issue, 
each share carrying the right to one vote. 
 
The above figure of 281,250,000 Ordinary Shares may be used by shareholders in 
the Company as the denominator for the calculations by which they will 
determine if they are required to notify their interest in, or a change to 
their interest in, the share capital of the Company under the Financial Conduct 
Authority's Disclosure and Transparency Rules. 
 
The directors of the EDX Medical accept responsibility for the contents of this 
announcement. 
 
For more information, please contact: 
 
EDX Medical PLC 
 
Dr Mike Hudson 
 
Tel: [phone] 
 
Peterhouse: 
 
Guy Miller 
 
Tel: [phone] 
 
Media House International, 
 
Ramsay Smith 
 
Tel:  [phone]: 
 
email: [e-mail] 
 
Notes for Editors: 
 
About EDX Medical Group 
 
EDX Medical develops and delivers innovative digital diagnostic products and 
services for cancer, heart disease, neurology and infectious disease testing, 
helping to predict disease risk, inform clinical decision-making and accelerate 
the development of new medicines. The company is listed on the Access Segment 
of the AQSE Growth Market (TIDM: EDX). 
 
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and 
life sciences entrepreneur with more than 30 years of experience in the sector, 
together with CEO, Dr Mike Hudson. 
 
By translating clinical insights into pragmatic solutions combining advanced 
biological and digital technologies, EDX Medical seeks to cost-effectively 
improve the detection of disease risk and personalise disease management in a 
timely fashion. Early disease detection and risk prediction is the most 
impactful way of reducing deaths and lowering the future costs of healthcare 
provision globally. 
 
EDX Medical operates a molecular biology and diagnostics laboratory 
in Cambridge, UK, and the 100%-owned subsidiary "Torax Biosciences Ltd" with a 
satellite laboratory in Ireland. EDX Medical provides testing and genomic 
sequencing services, undertakes quality assurance and has established expertise 
in the design, development, validation and sourcing of diagnostic testing 
solutions to ISO 13485. Key laboratory tests performed by the Company have been 
accredited to ISO 15189  by the United Kingdom Accreditation Service (UKAS).. 
 
www.edxmedical.co.uk 
 
https://www.toraxbiosciences.co.uk/ 
 
 
 
END 
 
 

(END) Dow Jones Newswires

April 26, 2023 09:15 ET (13:15 GMT)